A New Era of Generative AI for Everyone

Since the release of ChatGPT in 2022, the world has become increasingly exposed to the transformative potential of AI. This report by Criticaleye Partner Accenture explores the history of AI, while also looking to the future and how the commercial world can embrace Generative AI.

Key takeaways include:

  • Accenture found 40 percent of all working hours can be impacted by LLMs like Chat GPT.
  • 97 percent of global executives agree AI foundation models will enable connections across data types, revolutionising where and how AI is used.
  • Nearly 6 in 10 organisations plan to use ChatGPT for learning purposes and over half are planning pilot cases in 2023.




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Click here to download this insight
Asia Leadership Research Resu...

In this research, we surveyed senior leaders from Criticaleye’s Asia leadership Community to uncover the key trends and priorities influencing leadership performance across the region. Key findings from this ye...

Click here to download this insight
AlixPartners Disruption Index...

Criticaleye lead Partner AlixPartners' latest annual Disruption Index exposes a turbulent world in 2025, where geopolitical tensions, supply chain hurdles and rapid technology shifts continue to drive business disru...

Click here to download this insight
Global Incident Response Repo...

As digital technology adoption increases, the threat of cyber attacks on businesses also grows. This report by Criticaleye partner Palo Alto Networks analyses the emerging trends that are transforming the threat landsca...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 423




Google Rolls-Royce NATS LDC Workday Amazon UK Hitachi Solutions Lightsource bp Palo Alto Networks IBM Consulting Royal London Group Drax Group plc Accenture E.ON UK Experian AlixPartners Legal & General Investment Management Eightfold AI London Stock Exchange Group FTSE Women Leaders Review Salesforce Concentrix Activision Blizzard GlaxoSmithKline plc